Asthma, Healthy Volunteers
Conditions
Brief summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of different single and repeat doses of PIN201104 in healthy volunteers and in patients with asthma.
Interventions
DRUGPIN201104
IV or SC administration
DRUGPlacebo
IV or SC administration
Sponsors
Peptinnovate
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male and female subjects of non-childbearing potential age 18 to 65 years of age, and in good health as determined by medical history, physical examination, vital signs, electrocardiogram, and laboratory tests. * Written informed consent must be obtained before any assessment is performed. * Able to communicate well with the Investigator/designee.
Exclusion criteria
* Any known reaction to study drug or components * concurrent or recent infection or clinically significant conditions that may place subject at risk or interference with absorption, distribution or excretion of drugs * No QTcF interval ≥450 milliseconds, no QRS complex ≥120 milliseconds, at Screening * Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus (HIV) 1 and/or -2 antibodies at Screening. * Excessive use of caffeine-containing beverages * Urinary cotinine level indicative of smoking or history or regular use of tobacco- or nicotine containing products within 6 months before screening. * History of regular alcohol consumption within 6 months of screening 10. * Positive screen for drugs-of-abuse or cotinine. * Blood donation in excess of 500mL within 3 months. * Participation in another study with an experimental drug within 3 months of first IMP administration. * Exposure to more than 4 new chemical entities within 12 months before the first IMP administration. * Ongoing rhinitis that requires treatment. * Use of live vaccine 28 days before dosing with study drug until telephone follow-up and use of killed vaccine 14 days before dosing with study drug until telephone follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with TEAEs and number of events will be summarised by treatment | 21 days | Treatment Emergent Adverse Events after single and multiple dose administration will be collected at baseline and repeated until study completion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with clinically significant abnormal clinical chemistry variables will be summarised by treatment. | 14 days | Creatinine, glucose, triglycerides, urea, uric acid, bilirubin, cholesterol, sodium, potassium, alkaline phosphatase, AST, ALT and GGT will be collected at baseline and after single and multiple dose administration and repeated until Day 14. |
| Number of subjects with clinically significant abnormal electrocardiogram variables will be summarised by treatment. | 14 days | RR-interval, PR (PQ)-interval, QRS-duration, QT-interval, QTcB, QTcF and heart rate will be collected at baseline and after single and multiple dose administration and repeated until Day 14. |
| Number of subjects with clinically significant abnormal vital sign variables will be summarised by treatment. | 14 days | Blood pressure, pulse rate, oral body temperature and respiration rate will be collected at baseline and after single and multiple dose administration and repeated until Day 14. |
| Pharmacokinetics of PIN201104: The maximum observed plasma concentration (Cmax) | 24 hours | Cmax will be calculated after single and multiple IV dosing and single SC dosing of PIN201104 |
| Number of subjects with clinically significant abnormal haematology variables will be summarised by treatment. | 14 days | Haemoglobin, haematocrit, MCV, MCH, MCHC, RBC, WBC and differentials will be collected at baseline and after single and multiple dose administration and repeated until Day 14. |
| PK of PIN201104: Apparent terminal elimination half life in plasma (t1/2) | 24 hours | t1/2 will be calculated after single and multiple IV dosing and single SC dosing of PIN201104 |
| PK of PIN201104: Area under the curve from time zero to the last quantifiable concentration of PIN201104 (AUC0-t) | 24 hours | AUC0-t will be calculated after single and multiple IV dosing and single SC dosing of PIN201104 |
| PK of PIN201104: Apparent plasma clearance of PIN201104 (CL/F) | 24 hours | CL/F will be calculated after single and multiple IV dosing and single SC dosing of PIN201104 |
| PK of PIN201104: Apparent volume of distribution (Vz/F) | 24 hours | Vz/F will be calculated after single and multiple IV dosing and single SC dosing of PIN201104 |
| PK of PIN201104: The time to reach Cmax (Tmax) | 24 hours | Tmax will be calculated after single and multiple IV dosing and single SC dosing of PIN201104 |
Countries
United Kingdom
Outcome results
None listed